Tilray Announces Support for Clinical Trial Examining Cannabis and …

NANAIMO, British Columbia–(BUSINESS WIRE)–Tilray, a
global leader in medical cannabis research and production, today
announced a partnership with the Research Institute of the McGill
University Health Centre (RI-MUHC) in Montreal, one of the world’s
premier public academic and research institutions, to study the effects
of vaporized cannabis on symptoms associated with chronic obstructive
pulmonary disease (COPD).

The Phase
II trial
will study the efficacy of medical cannabis on
breathlessness, and exercise tolerance in symptomatic patients with
advanced COPD.

... read more at: http://www.businesswire.com/news/home/20170615005176/en/Tilray-Announces-Support-Clinical-Trial-Examining-Cannabis

Leave a Reply

Your email address will not be published. Required fields are marked *